Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Ipsen has licensed Genfit's elafibranor in a deal worth up to 480 million euros, betting the dual PPAR agonist can succeed in primary biliary cholangitis after…
Ipsen and Genfit have entered into a long-term strategic partnership granting Ipsen an exclusive worldwide license, excluding China, to elafibranor for primary…
Ipsen 9M-2024 results: Iqirvo (elafibranor) in 2L PBC had its first full quarter of sales following U.S. approval and contributed to total-sales growth; Ipsen…
Source summaries from our enrichment pipeline; follow links for originals.
All 13 sources with sentiment breakdown →
Ipsen and Genfit entered a long-term strategic partnership (announced 22-Dec-2021) granting Ipsen an exclusive worldwide license, excluding Greater China, to develop and commercialize elafibranor for primary biliary cholangitis. Genfit received EUR 120M (~$136M) upfront (paid December 2021), an 8% equity investment by Ipsen, milestones up to EUR 360M (~$407M) and tiered double-digit royalties of up to 20%. The bet paid off: the Phase 3 ELATIVE trial met its primary endpoint, and the U.S. FDA granted accelerated approval to Iqirvo (elafibranor) for PBC on 10-Jun-2024 as the first-in-class oral PPAR agonist in the indication, followed by EU conditional approval (Sept 2024) and UK MHRA authorization. First U.S. commercial sale triggered a EUR 48.7M milestone (invoiced Jun 2024, collected Aug 2024), and Iqirvo began contributing to Ipsen sales in 2H-2024. The de-risked asset validates Ipsen's rare-disease specialty-care strategy.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Ipsen S.A. / GENFIT (this deal) | 2021 | $543M | — |
| Ipsen S.A. / Exelixis Inc. | 2016 | $855M | 80 |
| Ipsen S.A. / Kartos Therapeutics, Inc. | 2026 | $1.8B | 68 |
| Ipsen S.A. / Memo Therapeutics AG | 2026 | $797M | 66 |
| Ipsen S.A. / Clementia Pharmaceuticals Inc. | 2019 | $1.3B | — |
| Ipsen S.A. / Marengo Therapeutics, Inc. | 2024 | $1.2B | — |
| Ipsen S.A. / Simcere Zaiming Pharmaceutical Co., Ltd. | 2025 | $1.1B | — |
← Browse all deals · How we score deals
More: 2021 deals · Ipsen S.A. deals · Gastroenterology deals